Nephrology Lab · DeCure for X
DeCure's autonomous Nephrology AI scientist is researching a drug-repurposing hypothesis for acute kidney injury — screening already-approved drugs against its 44-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
No approved-drug candidate for acute kidney injury is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
nuclear receptor subfamily 3 group C member 2 (NR3C2) — NR3C2 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
RCSB Protein Data Bank · entry 4PF3 · 1.1 Å · ligand 6-[1-(2,2-difluoro-3-hydroxypropyl)-5-(4-fluorophenyl)-3-methyl-1H-pyrazol-4-yl]-2H-1,4-benzoxazin-3(4H)-one (HFN). Experimental structure, not a prediction.
Acute kidney injury is described as a common hospital condition and an independent risk factor for in-hospital mortality. A 2008 review discusses tubular, inflammatory and vascular molecular targets that might lead to therapies to improve mortality and biomarkers for earlier diagnosis, but provides no patient data, no survival figures, and no tested intervention.
A 2016 rat study of acute renal ischaemia-reperfusion injury used microarray and bioinformatics to identify differentially expressed genes in the early stage of disease. The increase in expression measured by real-time PCR was essentially the same as the microarray multiple. The authors conclude that these genes may play a role in the pathogenesis of acute kidney injury. No drug was tested, no survival or functional outcome was measured, and the work is limited to rodent tissue.
The 2023 paper titled "Controversy 1: Proteins and new guidelines for acute kidney injury" does not study acute kidney injury at all. It reports a 10-week trial of whey, casein, and maltodextrin supplements in 60 overweight women. The whey group showed significant reductions in weight, body fat, and waist circumference compared with casein and control groups, and a higher decrease in energy intake (383 kcal/day versus 144 and 70 kcal/day). No mention is made of kidney function, injury biomarkers, or any renal outcome.
What is still missing: no clinical trial has tested any of the proposed molecular targets in patients with acute kidney injury; the rat gene-expression data have not been translated into a therapeutic; and the only human dietary study in this set did not measure kidney endpoints. Funding for adequately powered trials with renal outcomes, proper patient stratification by injury severity, and a clear molecular rationale for any candidate drug remain absent.
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
AbstractAcute kidney injury (AKI) is a very common condition encountered in a hospital setting. AKI is an independent risk factor for in-hospital mortality. In this review, we discuss in detail about the tubular, inflammatory and vascular molecular targets of AKI which may result in therapies to improve mortality and biomarkers for earlier diagnosis of AKI.
https://doi.org/10.5414/cnp70453AbstractOBJECTIVES: To study the differential genes expression in the early stage of acute renal ischemia-reperfusion injury and explore potential molecular mechanisms. METHODS: The ischemia-reperfusion model was made via clamping renal artery of rat. The microarray detection and bioinformatics analyzing of the genes expression were performed. Differentially expressed genes were screened and related cellular activities and signaling pathways were analyzed in early stage of acute kidney injury. Meanwhile, molecules closely relative to acute kidney injury were explored by establishing a biological network of the differentially expressed genes, and the results were verified by real-time PCR. RESULTS: ） which related to the acute kidney injury had an obvious differential expression in the early stage of disease. The multiple of increase was essentially the same as the multiple detected by microarray. CONCLUSIONS: may play a role in the pathogenesis of acute kidney injury.
https://doi.org/10.3969/j.issn.1004-5619.2016.06.001AbstractIt has been studied the effect of three kinds of supplements (whey, casein and maltodextrin, as control) in the regulation of food intake and satiety of 60 overweight women.After 10 weeks, significant differences (p < 0.001) were found with regard to reduction of weight, IMC, % fat and waist circumference in the whey group against casein and control groups.A higher decrease of energy intake (-383 kcal/day) was also found in women who ate whey supplements, while in the casein and control group the decrease was only -144 and -70 kcal/day respectively.Finally, satiety effect was more efficiently promoted by whey against casein and maltodextrins.
https://doi.org/10.20960/nh.04680Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
